Combining Bupropion SR With Venlafaxine, Paroxetine, or Fluoxetine: A Preliminary Report on Pharmacokinetic, Therapeutic, and Sexual Dysfunction Effects
J Clin Psychiatry 2002;63(3):181-186
© Copyright 2016 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: This study was designed to evaluate the effect of combining bupropion sustained release (SR) with venlafaxine, paroxetine, or fluoxetine in patients who reported unacceptable sexual dysfunction when treated with monotherapy with the latter 3 agents.
Method: Following a minimum of 6 weeks of antidepressant treatment with a selective serotonin reuptake inhibitor (SSRI) or venlafaxine (a serotonin-norepinephrine reuptake inhibitor), eligible subjects received a further 8 weeks of monitored combination therapy with bupropion SR at a dose of 150 mg/day with no alterations to index antidepressant dosing.
Results: There was a clinically significant benefit in 14 (78%) of 18 partial responders or nonresponders, and 33% (N=6) achieved a full response (c2=8.06, df=2, p=.017). Sexual dysfunction, particularly a decrease in orgasmic delay, was also significantly improved with combination therapy (men: paired t=-2.1, df=6, p=.08; women: paired t=-3.0, df=7, p=.02). Plasma monitoring of drugs and their metabolites revealed a statistically significant increase in venlafaxine levels (F=6.89, df=4,24; p=.001) accompanied by a decrease in O-desmethylvenlafaxine (F=14.26; df=4,24; p<.0005)
Conclusion: Bupropion had an effect on the pharmacokinetics of venlafaxine but not those of the SSRIs. Further investigation of combination treatments under randomized, double-blind conditions is recommended.